William Elmquist, PharmD, PhD

Distinguished Professor, Department of Pharmaceutics

William Elmquist

Contact Info

elmqu011@umn.edu

Office Phone 612-625-0097

Fax 612-626-2125

Office Address:
9-151A Weaver-Densford Hall

Mailing Address:
University of Minnesota
College of Pharmacy
Department of Pharmaceutics
9-177 Weaver-Densford Hall
308 Harvard St. SE
Minneapolis, MN 55455
USA

PharmD in Clinical Pharmacy, University of Minnesota

PhD in Pharmaceutics, University of Minnesota

BS in Pharmacy, University of Florida

BA in Zoology, University of South Florida

Research

Research Summary/Interests

  • Pharmacokinetics
  • Membrane transporters
  • CNS drug delivery

Publications

  • Agarwal S., Sane R., Ohlfest J.R. and Elmquist W.F. Role of breast cancer resistance protein (ABCG2/BCRP) in the distribution of sorafenib to the brain. J. Pharmacol. Exp. Ther. Oct 15, 2010. [Epub ahead of print] PMID:20952483.
  • Agarwal S., Sane R., Gallardo J., Ohlfest J. and Elmquist W.F. Brain distribution of gefitinib is limited by p-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) mediated active efflux. J. Pharmacol. Exp. Ther. 334(1): 147-55 (2010).
  • Bungay P.M., Wang T., Yang H. and Elmquist W.F. Utilizing transmembrane convection to enhance solute sampling and delivery by microdialysis: theory and in vitro validation. Journal of Membrane Science 348(1-2): 131-149 (2010).
  • Pan G., Winter T.N., Roberts J.C., Fairbanks C.A. and Elmquist W.F. Organic cation uptake is enhanced in BCRP1-transfected MDCKII cells. Molecular Pharmaceutics 7(1): 138-145 (2010).
  • Chen Y., Agarwal S., Shaik N.M., Chen C., Yang Z. and Elmquist W.F. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib. J. Pharmacol. Exp. Ther. 330(3): 956-63 (2009).
  • Shaik N., Giri N. and Elmquist W.F. Investigation of the micellar effect of pluronic P85 on p-glycoprotein inhibition: cell accumulation and equilibrium dialysis studies. J. Pharm. Sci. 98(11): 4170-90 (2009).
  • Giri N., Agarwal S., Shaik N., Pan G., Chen Y. and Elmquist WF. Substrate-dependent breast cancer resistance protein (Bcrp1/Abcg2)-mediated interactions: consideration of multiple binding sites in in vitro assay design. Drug Metab Dispos. 37(3): 560-70 (2009).
  • Giri N., Pan G., Shaik N., Terasaki T., Mukai C., Kitagaki S., Miyakoshi N. and Elmquist W.F. Investigation of the role of Abcg2/Bcrp1 on pharmacokinetics and CNS penetration of abacavir (ABC) and aidovudine (AZT) in the mouse. Drug Metab. Dispos. 36(8): 1476-84 (2008).
  • Shaik N., Pan G. and Elmquist W.F. Interactions of pluronic block copolymers on P-gp efflux activity: experience with HIV-1 protease inhibitors. J. Pharm. Sci. 97(12): 5421-33 (2008).
  • Shaik N., Giri N., Pan G. and Elmquist W.F. P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution. Drug Metabolism and Disposition 35(11): 2076-2085 (2007).
  • Pan G., Giri N. and Elmquist W.F. Abcg2/Bcrp1 mediates the polarized transport of anti-retroviral nucleosides abacavir and zidovudine. Drug Metabolism and Disposition 35(7): 1165-1173 (2007).
  • Pan G. and Elmquist W.F. Mitoxantone permeability in MDCKII cells is influenced by active influx transport. Molecular Pharmaceutics 4(3): 475-483 (2007).
  • Spitzenberger T.J., Heilman D., Diekmann C., Batrakova E., Kabanov A.V., Gendelman H.E., Elmquist W.F. and Persidsky Y. Novel delivery system enhances efficacy of antiretroviral therapy in animal model for HIV-1 encephalitis (HIVE). J. Cerebral Blood Flow and Metab. 27(5): 1033-1042 (2007).
  • Kirstein M.N., Brundage R.C., Elmquist W.F., Remmel R.P., Marker P.H., Guire D.E. and Yee D. Characterization of an in vitro cell culture bioreactor system to evaluate anti-neoplastic drug regimens. Breast Cancer Res. Treat. 96(3): 217-225 (2006).
  • Hitzman C.J., Elmquist W.F., Wattenberg L.W. and Wiedmann T.S. Development of a respirable, sustained release microcarrier for 5-fluorouracil I : In vitro assessment of liposomes, microspheres, and lipid coated nanoparticles. J. Pharm. Sci. 95(5): 1114-1126 (2006).
  • Hitzman C.J., Elmquist W.F. and Wiedmann T.J. Development of a respirable, sustained release microcarrier for 5-fluorouracil II : In vitro and in vivo optimization of lipid coated nanoparticles. J. Pharm. Sci. 95(5): 1127-1143 (2006).
  • Hitzman C.J., Wiedmann T.S., Dai H. and Elmquist W.F. Measurement of drug release from microcarriers by microdialysis. J. Pharm. Sci. 94(7): 1456-1466 (2005).
  • Bachmeier C.J., Spitzenberger T.J., Elmquist W.F. and Miller D.W. Quantitative Assessment of HIV-1 protease inhibitors interactions with drug efflux transporters in the blood brain barrier. Pharm. Res. 22(8): 1259-1268 (2005).
  • Dai H., Chen Y. and Elmquist W.F. Distribution of the novel antifolate Pemetrexed to the brain. J. Pharmacol. Exp. Therap. 315(1): 222-229 (2005).
  • Zhang Y., Schuetz J.D., Elmquist W.F. and Miller D.W. Plasma membrane localization of multidrug resistance-associated protein (MRP) homologues in brain capillary endothelial cells. J. Pharmacol. Exp Therap. 311(2): 449-455 (2004).
  • Benjamin R.K., Hochberg F.H., Fox E., Bungay P.M., Elmquist W.F., et al. Review of microdialysis in brain tumors, from concept to application: First Annual Carolyn Frye-Halloran Symposium. Neuro-Oncology 6(1): 65-74 (2004).
  • Dai H. and Elmquist W.F. Drug transport studies using quantitative microdialysis. Methods Mol. Med. 89: 249-264 (2003).
  • Sun H., Dai H., Shaik N. and Elmquist W.F. Drug efflux transporters in the CNS. Advanced Drug Delivery Reviews 55(1): 83-105 (2003).
  • Dai H., Marbach P., Lemaire M., Hayes M. and Elmquist W.F. Distribution of STI-571 to the brain is limited by p-glycoprotein mediated efflux. J. Pharmacol. Exp. Therap. 304(3): 1085-1092 (2003).
  • Dash A.K. and Elmquist W.F. Separation methods that are capable of revealing blood-brain barrier permeability. J. Chromatography B 797(1-2): 241-254 (2003).